{"public_id":"co_1a12e8f1c2279946de6494a62764eb09","status":"active","merged_into_public_id":null,"resolved_public_id":"co_1a12e8f1c2279946de6494a62764eb09","name":"sources of uncertainty","description":"Categories of uncertainty identified in cancer drug appraisals about clinical evidence, economic evidence, or decision making.","aliases":[],"types":["analytical category"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":44162853,"title":"Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals","citation_count":22,"url":"https://sah.borca.ai/papers/44162853"}],"claims":[{"public_id":"cl_6d189eee07e0d9a6010921a920062a66","text":"Six main sources of uncertainty were identified in NICE Appraisal Committee discussions of cancer drug appraisals.","corpus_id":44162853,"url":"https://sah.borca.ai/claims/cl_6d189eee07e0d9a6010921a920062a66"},{"public_id":"cl_9daeb26b8002f76797cf853082296518","text":"Two years of real-world data collection in the reformed Cancer Drugs Fund is unlikely to resolve the main types of uncertainty seen in recent cancer appraisals by itself.","corpus_id":44162853,"url":"https://sah.borca.ai/claims/cl_9daeb26b8002f76797cf853082296518"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_1a12e8f1c2279946de6494a62764eb09","url":"https://sah.borca.ai/concepts/co_1a12e8f1c2279946de6494a62764eb09"}